Alle her på tråden vet at du er desperat etter en billig inngang med ditt tåpelig innlegg kl 22tiden 😂😂😂😂😂

Hvem bryr seg om du kom deg ut eller ikke.

🤩🤩🤩The second part of the trial aims to optimize this dosing regimen, and preliminary results are expected to show similar or improved efficacy 🤩🤩🤩

The results from Verrica Pharmaceuticals' VP-315 Phase 2 trial for treating basal cell carcinoma will be announced on August 14, 2024. This announcement will include preliminary topline results from Part 2 of the trial [oai_citation:1,Verrica Pharmaceuticals to Report Second Quarter Financial](https://www.globenewswire.com/news-release/2024/08/06/2924953/0/en/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-Results-from-Part-2-of-Phase-2-Trial-of-VP-315-for-the-Treatment-of-Basal-Cell-Ca.html) [oai_citation:2,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 | VRCA Stock News](https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-to-report-second-quarter-financial-results-d35e73qjvfn8.html).

VP-315 is an oncolytic peptide immunotherapy designed to treat basal cell carcinoma non-surgically by inducing immunogenic cell death. In Part 1 of the trial, the 8 mg dose of VP-315 showed promising results, with 67% of treated tumors being completely cleared by day 49 post-treatment [oai_citation:3,Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting  - Verrica Pharmaceuticals](https://verrica.com/press_release/presentation-of-lesion-clearance-data-from-ongoing-ph-2-study-vp-315/). The second part of the trial aims to optimize this dosing regimen, and preliminary results are expected to show similar or improved efficacy [oai_citation:4,VP-315 Effective in Clearing Basal Cell Carcinoma Lesions](https://www.dermatologytimes.com/view/vp-315-effective-in-clearing-basal-cell-carcinoma-lesions).

For more detailed information, you can access the full announcement on Verrica's website or follow the webcast of the conference call on August 14 [oai_citation:5,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 | VRCA Stock News]

🤩🤩🤩

Lurer på om Verica Pharmaceutical er klar for et aldri så lite Rally nå!,
da den er meget oversolgt.
Relative Strength Index 26
Stochastic kun 5 !!

https://www.tradingview.com/symbols/OSL-LYTIX/technicals/

ØR kan ikke kjøpe eller selge uten å melde det til børsen.
Han er innsider. Han kjøpte aksjer sist i emien i april, tror jeg.
Han hadde ca 140000 aksjer v årskiftet ihht årsrapporten.

Ikke så verst med pluss på en rød-børs!
Jeg hadde forventet noe korreksjon i dag på avvente til kurshopp i morgen!

Q&A fra chatGPT 🤩
Interessant at det bekrefter faglige innlegget av stockwizard for 3 dager siden 🤩

How good could be the trial results of Part 2 of phase 2 VP-315 that comes 14 august.?

The anticipation surrounding the Part 2 results of the Phase 2 trial for VP-315 is significant, given its potential impact on the treatment of basal cell carcinoma (BCC). While exact outcomes remain speculative until the official release, several factors suggest the potential for positive results:

1. **Previous Success**: Verrica Pharmaceuticals has a track record of developing effective dermatological treatments. Their previous products, such as YCANTH (cantharidin), have been successful, which builds confidence in their current pipeline, including VP-315 [oai_citation:1,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP 315 for the Treatment of Basal Cell Carcinoma on August 14 2024 - MarketScreener](https://www.marketscreener.com/quote/stock/VERRICA-PHARMACEUTICALS-I-44247380/news/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-R-47582726/) [oai_citation:2,Verrica Pharmaceuticals to Report Second Quarter Financial](https://www.globenewswire.com/news-release/2024/08/06/2924953/0/en/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-Results-from-Part-2-of-Phase-2-Trial-of-VP-315-for-the-Treatment-of-Basal-Cell-Ca.html).

2. **Mechanism of Action**: VP-315 is derived from Lytix Biopharma's LTX-315, known for its novel mechanism targeting non-melanoma skin cancers. This innovative approach might offer advantages over existing therapies in terms of efficacy and safety [oai_citation:3,Verrica Pharmaceuticals to Report Second Quarter Financial](https://www.globenewswire.com/news-release/2024/08/06/2924953/0/en/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-Results-from-Part-2-of-Phase-2-Trial-of-VP-315-for-the-Treatment-of-Basal-Cell-Ca.html).

3. **Clinical Design**: The trial's design, focusing on a well-defined patient population with basal cell carcinoma, allows for clear assessment of VP-315's therapeutic benefits. This specificity enhances the likelihood of obtaining conclusive and favorable results [oai_citation:4,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 | VRCA Stock News](https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-to-report-second-quarter-financial-results-d35e73qjvfn8.html) [oai_citation:5,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 - MarketScreener](https://www.marketscreener.com/quote/stock/VERRICA-PHARMACEUTICALS-I-44247380/news/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-R-47566699/).

4. **Regulatory and Market Need**: Basal cell carcinoma is the most common type of skin cancer, and there's a substantial need for more effective and less invasive treatments. A successful trial outcome could meet this significant medical need, likely leading to positive reception from both the medical community and investors [oai_citation:6,Verrica Pharmaceuticals to Report Second Quarter Financial](https://www.globenewswire.com/news-release/2024/08/06/2924953/0/en/Verrica-Pharmaceuticals-to-Report-Second-Quarter-Financial-Results-and-Release-Preliminary-Topline-Results-from-Part-2-of-Phase-2-Trial-of-VP-315-for-the-Treatment-of-Basal-Cell-Ca.html).

The actual results will provide crucial data on the drug's efficacy, safety, and overall benefit-risk profile. Stakeholders are hopeful that the findings will affirm VP-315's potential as a groundbreaking treatment for basal cell carcinoma.

Tenker onsdag neste uke er startskuddet for noe stort 💥

Oppgangen denne uken blir som småpenger å regne 😎

Kjøp god strikk innen den tid for høydeskrekk 🥵🤣

Lytix har helt klart potensial til å bli mye større enn Algeta.

https://www.helse-bergen.no/fag-og-forsking/forsking/injisering-direkte-i-kreftsvulst-er-testet-pa-mennesker/

Det som ingen har tenkt over at ved så gode data at alle responderer (slik som ved part1), kan det bli raskt FDA godkjenning 🤩

The upcoming results for the VP-315 trial, expected on August 14, 2024, are anticipated to provide key insights into the efficacy and safety of this potential non-surgical treatment for basal cell carcinoma (BCC). VP-315 is an oncolytic peptide-based immunotherapy being developed by Verrica Pharmaceuticals. The trial's second part focused on optimizing the dosing regimen, following promising results from the first part where a significant portion of patients saw their tumors completely cleared.

The results from this trial could be particularly significant as they might confirm the effectiveness of VP-315 as a non-invasive alternative to surgery for BCC patients, potentially sparing them from procedures that often lead to pain, scarring, and infection. Investors and the medical community are keenly awaiting the data, which could indicate whether this treatment is ready to move forward into larger clinical trials or eventual regulatory approval [oai_citation:1,Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 - BioSpace](https://www.biospace.com/verrica-pharmaceuticals-to-report-second-quarter-financial-results-and-release-preliminary-topline-results-from-part-2-of-phase-2-trial-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-on-august-14-2024) [oai_citation:2,VP-315 Effective in Clearing Basal Cell Carcinoma Lesions](https://www.dermatologytimes.com/view/vp-315-effective-in-clearing-basal-cell-carcinoma-lesions) [oai_citation:3,Last Patient Dosed in Verrica's Phase 2 Study of VP-315 for Basal Cell Carcinoma](https://www.dermatologytimes.com/view/last-patient-dosed-in-verrica-s-phase-2-study-of-vp-315-for-basal-cell-carcinoma).

Det blir historisk på OB!
Algeta 2.0 🤩

@ Rassen: Lykke til med salget!😂😂😂😂😂😂😂
Håper i hvert fall at du ikke har investert dem på ULTI-møkk 🤪😂

Har noen anledning å oppdatere oss om top50?

Det er bare å sope til seg med begge hendene. https://www.investtech.com/no/market.php?CompanyID=101207

Skikkelig bra omsetning i dag

https://www.tradingview.com/symbols/OSL-LYTIX/technicals/

Litt ned fra overkjøpt nivå er positivt!

Presis om 48 timer får vi resultatene alle har lengtet etter 🤩
Ved merkante resultater som ved del 1, er det ikke utenkelig å søke til haste godkjenning!
Min drømmescenario (som ikke er veldig urealistisk) er at de med små svulster og100% effekt, får dette godkjent for primær behandling.
De med støtrre svulster med delvis effekt, får godkjent som neoadjuvant for å krympe svulsten til rimeligere kirurgi.

🚀🚀🚀

Blir rått 😁

🚀🚀🚀

Har noen anledning å oppdatere oss om top50?!

Håper det men muligheten for NANOV eller Ultimo er dessverre større enn at dette blir morro. Er vel derfor vi ser litt gevinstsikring nå for mange har nesten doblet pengene sine på tro og håp rally. Får håpe det kan bli litt morro nå og ikke bare skattefradrag, hadde jo vert fint å kunne bidra litt til Støre sin kasse så han kan dele ut litt mer på sine reiser.

Verrica Pharmaceutical fikk seg nå et bra løft i går kveld.
Fra en bunn 4,82 til 5,22 i After Hours.

Fortsetter oppover. https://www.tradingview.com/symbols/NASDAQ-VRCA/technicals/

https://www.marketwatch.com/investing/stock/vrca?mod=search_symbol

Opp 13,85 % After Hours på kurs $6 !

Spennende, kanskje noen der borte som vet noe andre ikke vet……

Om 4 timer får vi nyhetene vi har lengtet etter 🤩
Tror det blir en børspause under (og kanskje før) presentasjon ; dvs. ca. kl 14!
Suste sjans å ta påfyll 🤩🤩🤩

Lytix bør helt klart melde børspause for handel rundt kl 14 og holde stengt for handel inntill selskapet har kommet med en oppdatering/børsmelding på resultatene for å sikre lik informasjon til alle i markedet.

Tror meldingen er tidligere i dag formidlet med LYTIX ifm. oversetting og forberedelse til synchron børsmelding !
Blir ikke overrasket over litt lekkasjer!
Se på handelsmønter selv! Noen feier billige aksjer nå!

sånn ja,

Oslo SE, News13:37:28
LYTIX: Lytix Biopharma AS: Phase II preliminary results from skin cancer (BCC) clinical trial show an 86 percent overall reduction of tumor size, complete clearance in half of the patients and the potential to be utilized as a first-line therapy

fuck me, blir fart på jo

Hvor skal dette ende ??????

I første omgang (dvs. i dag) tror jeg kurs. 18,-.
Mener det var IPO kurs. Så får vi håpe på litt mediedekning og at noen analytikere tar tak i aksjen og at de kan komme med noen gode analyser.

har lurt på hvem som skulle ta over tronen for ultimo, lytix eller nykode, he he. Spennende fremover, men en god start så langt for lytix, fantastiske nyheter faktisk

GRATULERER alle med tålmodighet 🥳🥳

Kan gå høyt denne fremover nå 🤑🤑

🚀🚀🚀

@Rassen: er du i livet?! HEHE! 🤩

Det som er mest sannsynlige scenarioet:
- en del fornøyde kortsiktige selger ( har solgt) og kurs stabiliserer seg
- Verrica presentasjon i Nasdaq vekker oppmerksomheten , og kommer større gutta på banen!
- melding om fase 3 og milepælutbetaling
- melding om Malign melanom studien innen neste 2 uker gir enda mere boost!
-mediedekning som ifjor av TV2 osv
- tipper 50kr (+++) innen desember
-Kanskje FDA hastegodkjenning H1 2025
- Trolig tidlig godkjenning i Japan og noen andre liberale land! Dette skjedde med Verrica vortemiddel

Nå på TV2 🤩

https://www.tv2.no/direkte/jpybz/siste-nytt/66bca4d49aee5edcd9600067/lovende-resultater-for-norsk-kreftmedisin-stor-milepael